

**Area Drugs and Therapeutics Committee Meeting Minutes**

Wednesday 16th October 2024 10-12pm

Microsoft Teams Meeting

<b>Present:</b>	Mehrdad Malekian (Chair)	Graeme Bryson
	Victoria Gemmell (Minutes)	Chris Miller
	Colin Angus	Penny Brankin
	Rachael Kelly	Stephanie Dundas
	Kirsty Macfarlane	Gail Richardson
	Lynn Duff (deputizing for Tyra Smyth)	Alistair Brown (from item 7)
		Clare Carson (for items 4a and 8c)

<b>1. Apologies:</b>	Craig Thurtell
----------------------	----------------

<b>2. Declaration of Interest</b>	nil
-----------------------------------	-----

<b>Item</b>	<b>Notes</b>	<b>Action</b>
-------------	--------------	---------------

<b>3.</b>	<p><b><u>Minutes/Actions from the last meeting</u></b></p> <p>These were agreed as a true reflection of the meeting and can be published.</p>	
-----------	---	--

<b>4.</b>	<p><b><u>Matters Arising</u></b></p> <p><b>a) Management of Periop Adult Diabetic Guideline – Claire Carson</b> CC joined the group to discuss previously raised questions. Some small changes will be made and document returned for final approval.</p> <p><b>b) Maternity Varicella in Pregnancy Guideline - Kelly Ann Meldrum update awaited</b> An update was given by GR-VZIG has now been discontinued. The guideline will need amended to reflect this change. <b>Post Meeting Note</b>-There is a small supply of an unlicensed alternative which is being reserved for neonates. This can be accessed via the Rarely Used Urgent Medicines list arrangements via QE Hospital in GGC. Standard treatment has switched to aciclovir as per national guidance.</p>	
-----------	---	--

<b>5.</b>	<p><b><u>SMC Advice-CONFIDENTIAL</u></b></p> <p>Please see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website <b>after 10.00 am on Monday 11 November 2024.</b></p> <p><b><u>FULL SUBMISSIONS</u></b></p> <ul style="list-style-type: none"> <li>• lebrikizumab (Ebglyss) Almirall UK Limited SMC2707 <b>ACCEPTED RESTRICTED with PAS. REFER TO DERMATOLOGY</b></li> <li>• pembrolizumab (Keytruda) Merck Sharp &amp; Dohme UK Limited SMC2688 <b>NOT RECOMMENDED FOR NOTING</b></li> <li>• quizartinib film-coated tablets (Vanflyta®) Daiichi Sankyo UK Ltd SMC2699 <b>ACCEPTED with PAS. Await WoSCAN advice.</b></li> </ul>	
-----------	--	--

	<p><b><u>RESUBMISSION</u></b></p> <ul style="list-style-type: none"> <li>• axicabtagene ciloleucel dispersion for infusion (Yescarta) Kite, a Gilead company SMC2695 <b>ACCEPTED with PAS. Await WoSCAN advice.</b></li> </ul> <p><b><u>ABBREVIATED SUBMISSIONS</u></b></p> <ul style="list-style-type: none"> <li>• somapacitan (Sogroya) Novo Nordisk SMC2629 <b>ACCEPTED RESTRICTED. REFER to PAEDIATRICS (Restricted to use in children only)</b></li> <li>• tenetelapase 5,000 units (25 mg) powder for solution for injection (Metalyse®) Boehringer Ingelheim Limited SMC2697 <b>ACCEPTED. REFER TO STROKE MCN</b></li> <li>• bismuth subcitrate potassium/ metronidazole/ tetracycline hydrochloride hard capsules (Pylera®) Flynn Pharma Ltd SMC2701 <b>ACCEPTED RESTRICTED. REFER GASTROENTEROLOGY</b></li> </ul> <p><b><u>NON SUBMISSION</u></b></p> <ul style="list-style-type: none"> <li>• enzalutamide film coated tablets (Xtandi®) Astellas Pharma Ltd SMC2742</li> </ul> <p><b><u>DEFERRED ADVICE</u></b></p> <p><b><u>linzagolix film-coated tablets (Yselty®) Theramex Ireland Ltd SMC2631</u></b>  SMC reviewed linzagolix film-coated tablets (Yselty®), the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, in April 2024, however SMC advice was withheld in confidence at the time pending product availability. At the September meeting it was reported that SMC advice would be published in October, however, due to an issue with a delay to the supply chain the advice was withheld for a further month. It will now be issued to Boards on Friday 04 October 2024 and published on the SMC website on Monday 11 November 2024.  <b>REFER to GYNAECOLOGY</b></p> <p><b><u>FOR INFORMATION</u></b>  <b>Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.</b></p>	
6.	<p><b><u>SMC follow up</u></b>  RK outlined designation updates to medicines following September 24 meeting, including Bevespi. Medicines approaching the decision deadline were discussed and RK will take this forward with the relevant specialist teams.</p>	RK
7.	<p><b><u>Lanarkshire Formulary</u></b></p> <ol style="list-style-type: none"> <li><b>Tracy Tallo Stoma Care Nurse</b> - Agreed. RK will take this forward to update the formulary.</li> <li><b>Phyllocontin</b> - Agreed. RK will make the agreed changes to the formulary.</li> <li><b>Proposed update to Formulary SGLT2is</b> - Agreed. RK will make the agreed changes to the formulary and will continue to liaise with Cardiovascular specialist colleagues to subsequently update the Cardiovascular chapter in line with these changes.</li> <li><b>Proposed Formulary Amendments October 2024</b> - Agreed. This paper outlined Formulary amendments made following agreement at the August 2024 ADTC.</li> </ol> <p>GB gave a summary of plans for a West of Scotland Formulary. This will be a collaboration of Boards to create a shared medicines formulary. Members agreed this will be of benefit to all Boards involved. Ongoing updates with regards to this expected at subsequent meetings.</p>	RK

<p><b>8.</b></p>	<p><b><u>Clinical Protocols</u></b></p> <p>(a) <b>Tirzepatide for Weight Management – Izzy Howat</b> This was discussed. The committee feels greater clarity is required on plans for the longer term. This will be fed back to the author to be included as part of the patient pathway. It was agreed that the item will also need financial and operational approval, however approval was granted from a clinical position.</p> <p>(b) <b>Hypertensive Disorders in pregnancy - Kelly Anne Meldrum</b> This was discussed. There were a number of queries which will be fed back to the author for clarity.</p> <p>(c) <b>Management of SGLT2 Inhibitors for Heart Failure in Elective Surgery</b> <b>Clare Carson</b> This was a review of current guidance. No changes are necessary, and the document was approved.</p>	
<p><b>9.</b></p>	<p><b><u>ADTC New Medicines Decisions</u></b></p> <p>These were approved and will be submitted for publishing.</p>	
<p><b>10.</b></p>	<p><b><u>Unlicensed Medicines</u></b></p> <p>(a) Two flowcharts were presented which have been designed to support the updated ULM policy. The figures presented for authorisation were discussed and agreed as pragmatic and sensible. These have also been discussed at AMMB and approved. There will be extensive communications to share the new documents.</p>	
<p><b>11.</b></p>	<p><b><u>Medication and Clinical risk in Lanarkshire</u></b> <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a> nil</p>	
<p><b>12.</b></p>	<p><b><u>Regional Cancer Advisory Network</u></b> Review of NCMAG advice. It was discussed that NCMAG decisions are advisory, and not underpinned by policy, so going forward, these will require a decision to be made by ADTC and published. <b>Rachael to check with Kelly Baillie RE WoSCAN advice</b></p>	
<p><b>13.</b></p>	<p><b><u>Patient Safety Alerts</u></b> Nil</p>	
<p><b>14.</b></p>	<p><b><u>Lay member related items</u></b> Nil</p>	
<p><b>15.</b></p>	<p><b><u>Correspondence</u></b></p> <p>(a) <b><u>ADTC Collaborative</u></b> Nil</p>	
<p><b>16.</b></p>	<p><b><u>Pharmacy &amp; NMAHP Prescribing Governance</u></b> Nil</p>	

<p><b>17.</b></p> <p><b>a.</b></p> <p><b>b.</b></p>	<p><b><u>AOCB</u></b></p> <p>PA Medicines paper-Mehrdad Malekian</p> <p>The group agreed that ADTC is not the appropriate committee to approve this paper, as this would be practice out-with current regulatory frameworks and current Code of Practice. It was agreed that the Healthcare Governance Group would be more suitable.</p> <p>SMC representatives are coming to November meeting to give an update on SMC role and function.</p>	
<p><b>18.</b></p>	<p><b><u>Date of next meeting</u></b></p> <p>Wednesday 20th November 2024 10-12pm</p> <p>MS TEAMS</p>	